Complex legal battle concerns ‘skinny label’ strategy used by generic drug makers, prompting a $235 million award | Pharma ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

GlaxoSmithKline has approval on both sides ... and according to its label can be used to treat the blood cancer in adult patients who have received at least four prior therapies.

GSK has previously said that the broader label in first-line endometrial cancer will be the key to pushing annual sales of Jemperli into blockbuster territory. The drug generated £188 million ($ ...

Publicly disclosed details on the GSK agreement are summarized in the image ... I believe that in the future its label will be expanded to additional indications where there is need for an oral ...

The label for Jemperli plus chemotherapy in the U.S. was expanded to all adult patients with primary advanced or recurrent endometrial cancer in August 2024. Recently, GSK agreed to acquire IDRx ...

GSK plc GSK recently announced that EMA has accepted ... In September, the FDA expanded Dupixent’s label in the CRSwNP indication for use in adolescent patients aged 12 to 17 years.